Space Oddity – 2013 Acoustic Guitar Cover 60’s 70’s Rock Kiwi NASA Launch Special David Bowie NZ – Video

Posted on by


Space Oddity - 2013 Acoustic Guitar Cover 60 #39;s 70 #39;s Rock Kiwi NASA Launch Special David Bowie NZ
This is an Extended Kiwi Acoustic Guitar Cover Special with 4 simultaneous NASA launches from the East Otago Coastline of South Island NZ between Seacliff an...

By: Steph Sancia

Here is the original post:

Space Oddity - 2013 Acoustic Guitar Cover 60's 70's Rock Kiwi NASA Launch Special David Bowie NZ - Video

bestastrologerinindia Tantrik in India Canada America Australia Dubai world esa nasa roscosmos isa i – Video

Posted on by


bestastrologerinindia Tantrik in India Canada America Australia Dubai world esa nasa roscosmos isa i
World Famous Tantrik Astrologer, Astrology Remedies, Tantra Remedies, Best Astrologer, Aghori Tantrik, Psychic Astrologer, Vashikaran Specialist, Aghori Tant...

By: yoginath mayang

Here is the original post:

bestastrologerinindia Tantrik in India Canada America Australia Dubai world esa nasa roscosmos isa i - Video

NASA Announces Advanced Composite Research Partnership

Posted on by

NASA has selected six companies from five U.S. states to participate in a government-and-industry partnership to advance composite materials research and certification.

The companies are:

Bell Helicopter Textron Inc. of Fort Worth, Texas GE Aviation of Cincinnati Lockheed Martin Aeronautics Company of Palmdale, Calif. Northrop Grumman Aerospace Systems of Redondo Beach, Calif. Boeing Research & Technology of St. Louis United Technologies Corporation and subsidiary Pratt & Whitney of Hartford, Conn.

They were selected from 20 proposals submitted by teams from industry and academia in response to a call from the Advanced Composites Project, which is part of NASA's Aeronautics Research Mission Directorate's Integrated Systems Research Program. The project sought proposals to reduce the time for development, verification and regulatory acceptance of new composite materials and structures.

A panel of experts from NASA, the Federal Aviation Administration and the U.S. Air Force Research Laboratory reviewed the submissions and assessed them according to specific criteria. The six firms were chosen for their technical expertise, willingness and ability to share in costs, certification experience with government agencies, focused technology areas and partnership histories.

The first task for the partners is to develop articles of collaboration and establish how the alliance will work and how companies may be added in the future.

For more information about NASA Aeronautics research, go to: http://aeronautics.nasa.gov

Please follow SpaceRef on Twitter and Like us on Facebook.

Read more here:

NASA Announces Advanced Composite Research Partnership

Medical Professionalism and the Future of American Medicine – MacLean Conference 2011 – Video

Posted on by


Medical Professionalism and the Future of American Medicine - MacLean Conference 2011
Moderator: Mark Siegler November 11, 2011 3:54 Knights, Knaves or Pawns: Physicians as Accountable Professionals Christine Cassel, American Board of Internal...

By: MacLean Center

See the rest here:

Medical Professionalism and the Future of American Medicine - MacLean Conference 2011 - Video

True Jew News: Navy Yard Shooting, CDC Admits Western Medicine’s a "Fraud" {Part 6} finale’ – Video

Posted on by


True Jew News: Navy Yard Shooting, CDC Admits Western Medicine #39;s a "Fraud" {Part 6} finale #39;
http://www.blogtalkradio.com/gocchurch The Day of Atonement The Day of Atonement is Coming September 23rd Sundown -- September 24th Sundown, 2013. Be prepare...

By: hebrewstruth

See more here:

True Jew News: Navy Yard Shooting, CDC Admits Western Medicine's a "Fraud" {Part 6} finale' - Video

GCC eyes single medicine pricing

Posted on by

Gulf Cooperation Council (GCC) countries are poised to adopt a single medicine-pricing policy within the bloc as of 2014, Bahraini Minister of Health Sadiq Abdulkarim Al-Shihabi told local media.

He said the application of a unified pricing system and common procurement policy for drugs will contribute to lowering the price of medicine in GCC states.

The single pricing policy will be initially applied in government-owned facilities, which will be directly reflected on private pharmacies, he was quoted as saying.

He said an executive committee from the GCC Council of Health Ministers is following developments on the proposed single medicine-pricing policy.

The Bahraini minister admitted that there is disparity in medicine prices in the GCC states, as GCC countries differ in size. Saudi Arabia, for example, is a vast country that attracts many visitors for Haj and Umrah. This, in turn, affects the prices of medicine, he said.

GCC countries import 75 percent of their medicine supplies from other countries. States endeavored to set up medicine factories in cooperation with global medicine manufacturing firms with expertise and technical knowledge, said the minister.

He reaffirmed that many investors were willing to invest in this domain in GCC countries.

Go here to read the rest:

GCC eyes single medicine pricing

BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General …

Posted on by

WALTHAM, Mass., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) announced today the publication of the results of a clinical research study conducted at the Massachusetts General Hospital (MGH) that provide further evidence that elevated levels of galectin-3 are predictive of adverse outcomes in chronic heart failure patients and suggest that the prognostic value of this non-invasive biomarker may be enhanced when serial measurements are made over time.

In this clinical research study, which was recently published online in the European Journal of Heart Failure, first author Dr. Shweta Motiwala and colleagues of the Division of Cardiology at the Massachusetts General Hospital demonstrate that stable heart failure patients whose galectin-3 blood levels were greater than 20 ng/ml, when measured at three-month intervals, experienced 50% more cardiovascular events, including unplanned hospitalizations for heart failure, than patients whose galectin-3 levels were consistently lower than 20 ng/ml.1 Further, these research data, which were collected from over 900 outpatient visits, also found that increases in galectin-3 levels above a threshold value of 20 ng/ml between outpatient visits, and increases in galectin-3 levels in excess of 15% at any three-month interval, were also predictive of significantly increased risk of adverse outcomes, including unplanned hospitalizations.

"We believe that the results of this research study further support a large body of evidence regarding the utility of galectin-3 as a predictor of adverse outcomes in chronic heart failure," said Dr. Paul R. Sohmer, President and CEO of BG-Medicine, Inc. "From this study, it appears that serial outpatient testing for galectin-3 may provide additional information that may facilitate decisions regarding the clinical management of stable heart failure patients."

For this clinical research study, galectin-3 levels were measured in plasma samples that had been collected as part of the PROTECT study.2 The study enrolled 151 stable heart failure (HF) patients, with an average age of 63 years, who were followed for a median of 10 months. The HF patients who participated in the study had galectin-3 blood levels drawn at four time points during scheduled outpatient physician visits. Galectin-3 levels independently predicted cardiovascular events even after adjustment for clinically relevant variables such as treatment arm allocation, NT-proBNP level, and kidney function. No effect on galectin-3 levels was observed in association with heart failure medications that provided symptom-related or mortality-related benefits.

"Unplanned hospitalizations and unforeseen cardiovascular events are devastating to heart failure patients and their families, represent a significant challenge to health care providers and continue to be a leading cost burden on healthcare systems," stated Dr. Sohmer. "The results of this study from the Massachusetts General Hospital provide further evidence that galectin-3 testing may help to identify and facilitate triage of those heart failure patients who are at elevated risk of near-term adverse events and of deteriorating cardiac function."

The BGM Galectin-3(R) test is cleared by the FDA as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation.

About Galectin-3 and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day readmission. The BGM Galectin-3(R) test is to be used as an aid in assessing the prognosis of patients with chronic heart failure, in conjunction with clinical evaluation. For more information visit http://www.galectin-3.com

About BG Medicine, Inc.

BG Medicine, Inc. (BGMD) is a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.BG-Medicine.com. The BG Medicine Inc. logo is available for download here

Link:

BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General ...